May 31, 2018

Cellply receives €2.34m from SME Instrument program

With this grant funding, Cellply will industrialize the oncology diagnostic platform currently in Beta version, with the aim to expand clinical studies to hospitals and clinics in Europe.

Cellply, an Italian medtech company specialized in in-vitro diagnostic for oncology treatment has been selected by the European Commission among the winners of the prestigious Horizon 2020 – SME Instrument Phase 2 program, obtaining €2.3m funding for the Oncosmart project.

Cellply achieved this result after a highly competitive selection process which resulted in only 64 European companies funded among 1280 applicants. The grant received by Cellply is the largest one among the 9 Italian companies funded in the last SME Instrument call and one of the largest at EU level since the start of the SME instrument program in 2014.

«Cellply has a great opportunity to make a pivotal change in cancer care. We are very honored to receive this recognition that will accelerate the development of our platform and its clinical validation, by involving an important network of European oncology institutes» says Massimo Bocchi.